Artelo Biosciences

Artelo Biosciences

Pharmaceuticals
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

$1.1M

Market Cap • 11/5/2026

2011

(15 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,2

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

9,8

EPS

—

Market Cap

Market Cap

1,1M

EV

-3,1M

EV/Revenue

0

EV/EBITDA

0,3

EV/EBIT

0,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-1449,2%

Total Yield

-1449,2%

Payout

0%

Retained Earnings

-68,4M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

24,7%

CAGR Net Income 5Y

28,1%

Leverage

N.D./EBITDA

0,4

Debt/Equity

0%

Current Ratio

3

Quick Ratio

2,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium